%0 Journal Article %1 Schafer:2016:J-Cancer-Res-Clin-Oncol:27100354 %A Schäfer, N %A Gielen, G H %A Kebir, S %A Wieland, A %A Till, A %A Mack, F %A Schaub, C %A Tzaridis, T %A Reinartz, R %A Niessen, M %A Fimmers, R %A Simon, M %A Coch, C %A Fuhrmann, C %A Herrlinger, U %A Scheffler, B %A Glas, M %D 2016 %J J Cancer Res Clin Oncol %K dovitinib glioblastoma martin_glas %N 7 %P 1581-1589 %R 10.1007/s00432-016-2161-0 %T Phase I trial of dovitinib (TKI258) in recurrent glioblastoma %U https://www.ncbi.nlm.nih.gov/pubmed/27100354 %V 142 %X Dovitinib (TKI258) is an oral multi-tyrosine kinase inhibitor of FGFR, VEGFR, PDGFR β, and c-Kit. Since dovitinib is able to cross the blood-brain barrier and targets brain tumor-relevant pathways, we conducted a phase I trial to demonstrate its safety in recurrent glioblastoma (GBM).Patients with first or second GBM recurrence started treatment with the maximal tolerated dose (MTD) previously established in systemic cancer patients (500 mg/d, 5 days on/2 days off). A modified 3 + 3 design in three cohorts (500, 400, 300 mg) was used.Twelve patients were enrolled. Seventy-two adverse events (AEs) occurred and 16.7 % of AEs were classified as ≥CTC grade 3 toxicity, mainly including hepatotoxicity and hematotoxicity. Only one out of six patients of the 300-mg cohort showed grade 3 toxicity. The PFS-6 rate was 16.7 %, and it was not associated with detection of the FGFR-TACC gene fusion in the tumor.Dovitinib is safe in patients with recurrent GBM and showed efficacy in only some patients unselected for target expression. The recommended phase II dose of 300 mg would be substantially lower than the recently established MTD in systemic cancer patients. Further personalized trials are recommended.

@article{Schafer:2016:J-Cancer-Res-Clin-Oncol:27100354, abstract = {Dovitinib (TKI258) is an oral multi-tyrosine kinase inhibitor of FGFR, VEGFR, PDGFR β, and c-Kit. Since dovitinib is able to cross the blood-brain barrier and targets brain tumor-relevant pathways, we conducted a phase I trial to demonstrate its safety in recurrent glioblastoma (GBM).Patients with first or second GBM recurrence started treatment with the maximal tolerated dose (MTD) previously established in systemic cancer patients (500 mg/d, 5 days on/2 days off). A modified 3 + 3 design in three cohorts (500, 400, 300 mg) was used.Twelve patients were enrolled. Seventy-two adverse events (AEs) occurred and 16.7 % of AEs were classified as ≥CTC grade 3 toxicity, mainly including hepatotoxicity and hematotoxicity. Only one out of six patients of the 300-mg cohort showed grade 3 toxicity. The PFS-6 rate was 16.7 %, and it was not associated with detection of the FGFR-TACC gene fusion in the tumor.Dovitinib is safe in patients with recurrent GBM and showed efficacy in only some patients unselected for target expression. The recommended phase II dose of 300 mg would be substantially lower than the recently established MTD in systemic cancer patients. Further personalized trials are recommended.}, added-at = {2017-05-26T08:37:51.000+0200}, author = {Sch{\"a}fer, N and Gielen, G H and Kebir, S and Wieland, A and Till, A and Mack, F and Schaub, C and Tzaridis, T and Reinartz, R and Niessen, M and Fimmers, R and Simon, M and Coch, C and Fuhrmann, C and Herrlinger, U and Scheffler, B and Glas, M}, biburl = {https://www.bibsonomy.org/bibtex/23577dabb573da5cfe4e7f13eb134a6e0/marcsaric}, description = {Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. - PubMed - NCBI}, doi = {10.1007/s00432-016-2161-0}, interhash = {6fe1a354214b01c9321aa8cf2a9d55f7}, intrahash = {3577dabb573da5cfe4e7f13eb134a6e0}, journal = {J Cancer Res Clin Oncol}, keywords = {dovitinib glioblastoma martin_glas}, month = jul, number = 7, pages = {1581-1589}, pmid = {27100354}, timestamp = {2017-05-26T08:37:51.000+0200}, title = {Phase I trial of dovitinib (TKI258) in recurrent glioblastoma}, url = {https://www.ncbi.nlm.nih.gov/pubmed/27100354}, volume = 142, year = 2016 }